State of the art therapy in multiple myeloma and future perspectives
- 31 July 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (11) , 1591-1600
- https://doi.org/10.1016/j.ejca.2005.11.040
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Thalidomide–dexamethasone as primary therapy for advanced multiple myelomaAmerican Journal of Hematology, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Comparison of high‐dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaCancer, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999